The stock is likely to react positively to the improved financial position and clinical progress, but traders should monitor for resolution of the FDA clinical hold on TXM and upcoming data from the challenge trial as key catalysts. The non-recurring nature of the $26.6M gain means future fundamentals hinge on clinical execution.
Price Chart
Executive Summary
Traws Pharma reported a dramatic year-over-year swing from a $166.5M loss in 2024 to a $9.2M net income in 2025, driven by a $26.6M gain from warrant liability revaluation and $2.8M in revenue from a terminated license agreement. The company also secured a $60M PIPE financing, extending its runway into Q1 2027, while advancing its lead candidates TXM for influenza and ratutrelvir for COVID-19.
Key Financial Metrics
Key Facts
- Net income of $9.2M in 2025 vs. net loss of $166.5M in 2024
- EPS of $0.83 basic and $0.82 diluted vs. $35.21 loss per share in 2024
- Revenue increased to $2.8M from $0.2M due to deferred revenue recognition from a terminated license
- $26.6M gain from change in fair value of warrant liability drove profitability
- Completed $60M PIPE financing with $10M upfront and milestone-based warrants, extending cash runway to Q1 2027
- Lead candidate TXM advancing in a planned human influenza challenge trial in Q2 2026
- FDA clinical hold remains on TXM program due to toxicology concerns
Financial Impact
Net income improved by $175.7M YoY; $26.6M non-cash gain from warrant revaluation was primary driver. $60M financing provides runway into Q1 2027.
Risk Factors
- FDA clinical hold on TXM program remains unresolved
- Profitability driven by non-recurring $26.6M warrant revaluation gain
- Dependence on future milestone financing and shareholder approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274858 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3330 (+4.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3330 (+5.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3330 (−11.44%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3330 (+11.44%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3330 (+38.33%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3330 (+51.38%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3330 (+51.38%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3330 (+56.18%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3330 (−56.18%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3330 (−56.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers